FDA requires black-box warning on post-chemo anemia drugs

03/10/2007 | NYTimes.com · Washington Post, The

Makers of drugs used to treat patients with anemia that results from kidney failure or chemotherapy must add a black-box warning due to recent studies suggesting possible heart problems or death, the FDA says. The agency issued the new requirement for Amgen's Aranesp and Epogen and Johnson & Johnson's Procrit, both of in the Epo class of drugs.

View Full Article in:

NYTimes.com · Washington Post, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC